multi-virus-specific T cells TI1 therapy (QIMR Berghofer Medical Research Institute)

N/A

Report date: 2025/01/26 16:26:40

Base Information

Drug Namemulti-virus-specific T cells TI1 therapy (QIMR Berghofer Medical Research Institute)
Drug Alias Nameallogeneic multi-virus-specific T-cell therapy (QIMR Berghofer Medical Research Institute)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionT lymphocytes stimulantsImmunostimulants
TargetsUpdating
Therapy Area/IndicationsBK Polyomavirus InfectionsEpstein-Barr Virus InfectionsCytomegalovirus Infections +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustralia and New Zealand
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesCouncil of The Queensland Institute of Medical Research
China Registration ClassN/A

Develop Information

Active CompaniesCouncil of The Queensland Institute of Medical Research
Inactive CompaniesN/A
Active IndicationsBK Polyomavirus InfectionsEpstein-Barr Virus InfectionsCytomegalovirus Infections +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A